Elucidating the Association Between First-Line Antimalarial Drug Susceptibility and Patient Outcomes in African Severe Malaria: A Prospective Cohort Study Towards Improving Survival Rates

Elucidating the Association Between First-Line Antimalarial Drug Susceptibility and Patient Outcomes in African Severe Malaria: A Prospective Cohort Study Towards Improving Survival Rates - Elucidating the Association Between First-Line Antimalarial Drug Susceptibility and Patient Outcomes in African Severe Malaria

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061551

Enrollment

150

Registered

2026-05-15

Start date

2026-05-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 6 months or older, weighing 5 kg or more, who meet the 2025 WHO diagnostic criteria for severe malaria.

Exclusion criteria

Exclusion criteria: Patients who have received antimalarial treatment within 2 weeks prior to enrollment.

Design outcomes

Primary

Measure	Time frame
Change in pSOFA score from baseline to Day 3 (Delta pSOFA)	—

Secondary

Measure	Time frame
Changes in PELODS-2 score, PIM3 score, lactate, hemoglobin, total bilirubin, and platelet count (measured pre-treatment, on Day 3 of treatment, and at discharge); mortality rate; rate of dialysis initiation; ICU admission rate; incidence of neurological sequelae; blood transfusion volume; length of hospital stay; length of ICU stay; time to resolution of severe malaria criteria; and medical costs.	—

Measure

Time frame

Changes in PELODS-2 score, PIM3 score, lactate, hemoglobin, total bilirubin, and platelet count (measured pre-treatment, on Day 3 of treatment, and at discharge); mortality rate; rate of dialysis initiation; ICU admission rate; incidence of neurological sequelae; blood transfusion volume; length of hospital stay; length of ICU stay; time to resolution of severe malaria criteria; and medical costs.

—

Countries

Africa

Contacts

Public ContactAkihiro Kosuge

Juntendo University, Faculty of Medicine Department of Tropical Medicine and Parasitology

a.kosuge.xb@juntendo.ac.jp03-5802-1043

Outcome results